The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 22nd 2023
Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
Register Now!
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
View More
Clinical Consultations: Improving Outcomes By Addressing Health Care Disparities in Heart Failure Care
View More
Understanding Best Care Practices for Hemorrhagic Stroke – A Focus on the Role of DOAC Reversals
View More
Addressing Healthcare Inequities in Cardiac Amyloidosis: Interventions Aimed at Improving Care for All Patients
View More
The 6th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Transfusion-Related Iron Overload–Evidence-Based Approaches to Improve Chelation Outcomes
View More
Community Practice Connections™: Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management
View More
Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias
View More
Medical Crossfire®: Updates in Continuous Glucose Monitoring—Having the Important Conversations With Your Patients
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH
September 15th 2023Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.
Bempedoic Acid Proves Cardiovascular Benefit Across Glycemic Spectrum in New Analysis
August 30th 2023A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.
Biden Administration, CMS Reveal First 10 Drugs Set for Price Negotiation
August 29th 2023On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.
FRAIL-AF: Switching to NOACs in Older, Frail Patients Linked to Increased Bleeding Risk
August 28th 2023Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.
Diabetes Dialogue: STEP-HFpEF Reaction
August 27th 2023Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
August 27th 2023With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.
Semaglutide for HFpEF? Breaking Down the STEP-HFpEF Trial, with Javed Butler, MD
August 27th 2023Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.
Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity
August 25th 2023Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.